Adult-onset Still’s disease (AOSD) is a rare, polygenic autoinflammatory syndrome with a pathogenesis similar to systemic juvenile inflammatory arthritis. Join Drs. Petros Efthimiou and Olga Petryna as they discuss making the diagnosis of AOSD through interpretation of clinical and laboratory findings and careful exclusion of other diseases. The faculty review the evidence related to the variety of medications often used to treat patients with AOSD, focusing on canakinumab, the only medication approved in the United States for the disease.
Exploring Best Practices for Diagnosis & Management of Adult-Onset Still's Disease
Claim This Podcastby AOSD Podcast
1.0(1 reviews)
4 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇺🇸
Podcast Overview
Adult-onset Still’s disease (AOSD) is a rare, polygenic autoinflammatory syndrome with a pathogenesis similar to systemic juvenile inflammatory arthritis. Join Drs. Petros Efthimiou and Olga Petryna as they discuss making the diagnosis of AOSD through interpretation of clinical and laboratory findings and careful exclusion of other diseases. The faculty review the evidence related to the variety of medications often used to treat patients with AOSD, focusing on canakinumab, the only medication approved in the United States for the disease.
Language
🇺🇲
Publishing Since
7/9/2021
1 verified contact email on file for Exploring Best Practices for Diagnosis & Management of Adult-Onset Still's Disease
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 9, 2021
Case Studies
<ul> <li>The diagnosis of adult-onset Still’s disease requires extensive evaluation guided by whether systemic or joint signs/symptoms predominate</li> <li>Initial disease-modifying therapy with methotrexate is often inadequate to provide symptom relief</li> <li>Treatment modification with targeted biologic treatment is generally required to achieve treatment goals</li> </ul>
July 9, 2021
Treatment Strategies & Options
<ul> <li>Goals of treatment: control inflammation, prevent joint and organ damage, minimize treatment-related adverse events; relieve patient burden</li> <li>A wide variety of non-biologic and biologic medications are used for treatment, but are supported with limited evidence</li> <li>Canakinumab is the only medication approved by the US Food and Drug Administration for the treatment of patients with adult-onset Still’s disease based, in part, on the results of the phase 3 CONSIDER trial</li> <li>There is no standardized approach to patient monitoring, but is closely tied to the goals of treatment</li> </ul>
July 9, 2021
Recognition & Diagnosis
<ul> <li>Adult-onset Still’s disease is a diagnosis of exclusion</li> <li>Yamaguchi criteria are useful to classify the disease</li> </ul>
4 total episodes available
Deep-dive analytics for Exploring Best Practices for Diagnosis & Management of Adult-Onset Still's Disease
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Exploring Best Practices for Diagnosis & Management of Adult-Onset Still's Disease?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.